Biostate AI Launches Total RNA Sequencing and Free Data Analysis AI
08 Julio 2024 - 10:00AM
Business Wire
Biostate AI, the scalable biodata foundry startup, emerges from
stealth today with the launch of two service products: Total RNA
sequencing and Copilot for RNAseq data analysis. Biostate AI aims
to partner and collaborate with academic researchers, hospital
biorepositories, and pharma/biotech companies, leveraging its new
technologies for scalable multiomic data collection, scientific
discovery, and AI training.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240708652997/en/
"The successful training of any AI well requires large
quantities of relevant and high-quality data," says David Zhang,
co-founder and CEO of Biostate AI. "Biostate AI has developed the
instrumental technologies to facilitate the collection of more
biological data at lower costs. We are pleased to offer these
capabilities to academic and industry partners and
collaborators."
Biostate's Total RNA sequencing uses its patent-pending
Barcode-Integrated Reverse Transcription (BIRT) technology to
affordably, scalably, and comprehensively analyze all types of RNA.
In contrast, traditional gene expression profiling using RNA
sequencing (RNAseq) typically only captures information from
messenger RNA, which accounts for less than 10% of all known RNA
species. Biologically important classes of non-coding RNA include
long non-coding RNAs (lncRNAs), micro RNAs (miRNAs), circular RNAs
(circRNAs), and enhancer RNAs (eRNAs).
Biostate AI has filed 9 pending patents on its technologies, and
collaborates with a number of industry partners on new technology
development, including Twist Bioscience. Biostate AI also recently
exclusively in-licensed further intellectual property (IP) from the
California Institute of Technology (Caltech) to expand the range of
biomolecules analyzed. These technologies will also reduce the
amount of animal testing performed by pharma and biotech companies
in preclinical studies.
To date, Biostate AI has raised more than $4M in venture
funding. Matter Venture Partners led the funding round, with
participation from institutional investors Vision Plus Capital,
Catapult VC, and the California Institute of Technology through the
Caltech Seed Fund. Individual investors in the round included Dario
Amodei (CEO of Anthropic), Joris Poort (CEO of Rescale), Michael
Schnall-Levin (CTO of 10X Genomics) and Emily Leproust (CEO of
Twist Bioscience).
"AI is the next frontier and AI needs data, and biological data
is a lot harder to get than text or images. We are excited about
the potential for Biostate's technology to dramatically lower the
cost of collecting RNAseq datasets," said Haomiao Huang, Founding
Partner at Matter Venture Partners. "As a US company, Biostate's
affordable AI-embedded CRO services are much needed today as the
supply of preclinical research services shrinks due to geopolitical
tensions."
Biostate AI also launched OmicsWeb Copilot
(http://www.omicsweb.com/) today, a conversational AI launched to
help biologists analyze and visualize data. Copilot leverages state
of the art large-language models (LLMs) to understand user requests
and intent to build customized software and scripts for data
analysis. In addition to analyzing the user's own uploaded data,
Copilot provides access to over 1000 unique RNAseq datasets
collected by the Biostate team. Copilot is being fine-tuned on 5000
proprietary RNAseq datasets, enabling advanced analyses and anomaly
detection. Biostate AI offers the Copilot platform at no cost to
academic and nonprofit users and researchers.
"Bioinformatic analysis of RNAseq and other omics data is a
highly complex, multi-step process that currently takes many hours
of dedicated specialized programming," said Ashwin Gopinath,
co-founder and CTO of Biostate AI. "As we scaled up our RNAseq data
collection in the past year, we started building OmicsWeb Copilot
as an internal tool to help our scientists make sense of the data.
And then we realized other people may also find this tool useful,
so we're opening it up to the general public for free."
The ultimate goal of Biostate AI is to build AI that can predict
human and animal health changes, including toxicity and efficacy
responses to drugs. The team has recently demonstrated RNA
expression in blood taken from rats before drug dosing can predict
survival with a Hazard Ratio of 8. To scale this proof-of-concept
demonstration to prediction of toxicity in humans for novel drugs,
far more data must be collected, analyzed, and fed into AI models
for training. In this course of this data collection, petabytes of
RNAseq and other omics data must be collected, interpreted, and
tokenized.
About Biostate AI. Biostate AI is a startup founded in
2023 with the mission of developing generative AI that can benefit
all of human health. With offices and laboratories in Palo Alto, CA
and Houston, TX, Biostate AI collaborates with academic, nonprofit,
and industry partners on technology development and multiomic
biodata collection. Please reach out at partnerships@biostate.ai
regarding potential interest in collaborations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708652997/en/
Kristina Beaman Kristina.beaman@biostate.ai